Prespecified subgroup analysis of a Danish trial in 131,276 adults ≥60 randomised to RSVpreF or no vaccine: effectiveness against RSV hospitalisation was 60.5% (CI crossing null) with immunosuppression vs 92.3% without; no significant interaction (p=0.22).
Secondary analysisn = 131,276
Reimer Jensen et al. RSV prefusion F vaccine effectiveness in older adults with immunosuppression: a prespecified analysis of the DAN-RSV trial